- Home
- ECPG vs CANF Comparison
ECPG vs CANF Comparison
Compare ECPG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- CANF
- Stock Information
- Founded
- ECPG 1998
- CANF 1994
- Country
- ECPG United States
- CANF Israel
- Employees
- ECPG N/A
- CANF N/A
- Industry
- ECPG Finance Companies
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- CANF Health Care
- Exchange
- ECPG Nasdaq
- CANF Nasdaq
- Market Cap
- ECPG N/A
- CANF 7.9M
- IPO Year
- ECPG 1999
- CANF N/A
- Fundamental
- Price
- ECPG $34.41
- CANF $1.15
- Analyst Decision
- ECPG Strong Buy
- CANF Strong Buy
- Analyst Count
- ECPG 3
- CANF 2
- Target Price
- ECPG $62.67
- CANF $14.00
- AVG Volume (30 Days)
- ECPG 339.8K
- CANF 423.1K
- Earning Date
- ECPG 05-07-2025
- CANF 05-06-2025
- Dividend Yield
- ECPG N/A
- CANF N/A
- EPS Growth
- ECPG N/A
- CANF N/A
- EPS
- ECPG N/A
- CANF N/A
- Revenue
- ECPG $1,316,361,000.00
- CANF $674,000.00
- Revenue This Year
- ECPG $21.62
- CANF $461.72
- Revenue Next Year
- ECPG $10.12
- CANF N/A
- P/E Ratio
- ECPG N/A
- CANF N/A
- Revenue Growth
- ECPG 7.66
- CANF N/A
- 52 Week Low
- ECPG $26.45
- CANF $1.22
- 52 Week High
- ECPG $51.77
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ECPG 54.30
- CANF 35.40
- Support Level
- ECPG $28.93
- CANF $1.14
- Resistance Level
- ECPG $34.97
- CANF $1.27
- Average True Range (ATR)
- ECPG 2.20
- CANF 0.12
- MACD
- ECPG 0.84
- CANF -0.02
- Stochastic Oscillator
- ECPG 93.08
- CANF 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).